291 related articles for article (PubMed ID: 31812666)
21. Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.
Maekawa T; Sasaoka T; Azuma S; Ichikawa T; Melrose HL; Farrer MJ; Obata F
BMC Neurosci; 2016 Nov; 17(1):77. PubMed ID: 27903237
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
23. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
24. The Role of LRRK2 in Intracellular Organelle Dynamics.
Boecker CA
J Mol Biol; 2023 Jun; 435(12):167998. PubMed ID: 36764357
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.
Taymans JM; Cookson MR
Bioessays; 2010 Mar; 32(3):227-235. PubMed ID: 20127702
[TBL] [Abstract][Full Text] [Related]
26. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
De Miranda BR; Castro SL; Rocha EM; Bodle CR; Johnson KE; Greenamyre JT
Neurobiol Dis; 2021 Jun; 153():105312. PubMed ID: 33636387
[TBL] [Abstract][Full Text] [Related]
27. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
[TBL] [Abstract][Full Text] [Related]
28. Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.
Cookson MR
Biochem Soc Trans; 2016 Dec; 44(6):1603-1610. PubMed ID: 27913668
[TBL] [Abstract][Full Text] [Related]
29. Mutations in LRRK2 potentiate age-related impairment of autophagic flux.
Saha S; Ash PE; Gowda V; Liu L; Shirihai O; Wolozin B
Mol Neurodegener; 2015 Jul; 10():26. PubMed ID: 26159606
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.
Islam MS; Moore DJ
Biochem Soc Trans; 2017 Feb; 45(1):163-172. PubMed ID: 28202670
[TBL] [Abstract][Full Text] [Related]
31. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E
Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
[TBL] [Abstract][Full Text] [Related]
33. The Role of LRRK2 in Neurodegeneration of Parkinson Disease.
Rui Q; Ni H; Li D; Gao R; Chen G
Curr Neuropharmacol; 2018; 16(9):1348-1357. PubMed ID: 29473513
[TBL] [Abstract][Full Text] [Related]
34. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice.
Tong Y; Yamaguchi H; Giaime E; Boyle S; Kopan R; Kelleher RJ; Shen J
Proc Natl Acad Sci U S A; 2010 May; 107(21):9879-84. PubMed ID: 20457918
[TBL] [Abstract][Full Text] [Related]
35. α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells.
Kondo K; Obitsu S; Teshima R
Biol Pharm Bull; 2011; 34(7):1078-83. PubMed ID: 21720016
[TBL] [Abstract][Full Text] [Related]
36. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
37. Exploring the focal role of LRRK2 kinase in Parkinson's disease.
Kumar S; Behl T; Sehgal A; Chigurupati S; Singh S; Mani V; Aldubayan M; Alhowail A; Kaur S; Bhatia S; Al-Harrasi A; Subramaniyan V; Fuloria S; Fuloria NK; Sekar M; Abdel Daim MM
Environ Sci Pollut Res Int; 2022 May; 29(22):32368-32382. PubMed ID: 35147886
[TBL] [Abstract][Full Text] [Related]
38. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
[TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.
Andersen MA; Christensen KV; Badolo L; Smith GP; Jeggo R; Jensen PH; Andersen KJ; Sotty F
Neurobiol Dis; 2018 Aug; 116():13-27. PubMed ID: 29680709
[TBL] [Abstract][Full Text] [Related]
40. Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease.
Rivero-Ríos P; Gómez-Suaga P; Fernández B; Madero-Pérez J; Schwab AJ; Ebert AD; Hilfiker S
Biochem Soc Trans; 2015 Jun; 43(3):390-5. PubMed ID: 26009181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
